Author

David G. Justus

Boston Children's HospitalORCID 0000-0003-1345-0257Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:CRISPR screen· 1 Research Focus:perturbation response prediction· 1 Assay:proteomics· 1

Frequent Co-Authors

Daniel E. BaueriD· 2 shared John P. ManisiD· 2 shared Adelaide Herman· 1 shared Archana Verma· 1 shared Bo LiuiD· 1 shared Braden PateiD· 1 shared Chaitanya Kumar JaladankiiD· 1 shared Chong GaoiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

Daniel E. BauerORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cell BiologybioRxivPreprintSep 17, 2025

Discovery of A Small Molecule non-IMiD Degrader of ZBTB7A for the Treatment of β-hemoglobinopathies

Jun Liu, Ziyang Shen, Shin‐Young Park…·Li Chai

This paper discovers and characterizes SH6, a small molecule degrader of ZBTB7A that increases fetal hemoglobin expression in erythroid cells and shows therapeutic potential for β-hemoglobinopathies.

3 citations

humanproteomics

𝕏 PostBluesky

GeneticsCell stem cellPeer-reviewedDec 12, 2024

Gene editing without ex vivo culture evades genotoxicity in human hematopoietic stem cells

Jing Zeng, My Anh Nguyen, Pengpeng Liu…·Daniel E. Bauer

This study shows that gene editing of HSCs without ex vivo culture reduces genotoxicity while maintaining therapeutic efficacy for beta-hemoglobinopathy treatment.

34 citationstop 3%

humanCRISPR screen

𝕏 PostBluesky